NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $1.32 -0.37 (-22.13%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexaria Bioscience Stock (NASDAQ:LEXX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$1.23▼$1.4550-Day Range$1.21▼$1.8252-Week Range$1.15▼$4.44Volume367,491 shsAverage Volume169,886 shsMarket Capitalization$23.11 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewLexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Read More… Lexaria Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreLEXX MarketRank™: Lexaria Bioscience scored higher than 40% of companies evaluated by MarketBeat, and ranked 435th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has received no research coverage in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.59) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.18% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Lexaria Bioscience has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.18% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Lexaria Bioscience has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.38 News SentimentLexaria Bioscience has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders26.40% of the stock of Lexaria Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address LEXX Stock News HeadlinesLexaria provides GLP-1 update following industry developmentsApril 23 at 5:56 PM | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23 at 11:53 AM | finance.yahoo.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 25, 2025 | Porter & Company (Ad)We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Bioscience begins dosing for GLP-1 study #5April 3, 2025 | markets.businessinsider.comLexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | finanznachrichten.deLexaria Bioscience Corp.: Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-ArmFebruary 24, 2025 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Granted Two New DehydraTECH Patents for Treatment of EpilepsyFebruary 11, 2025 | finanznachrichten.deSee More Headlines LEXX Stock Analysis - Frequently Asked Questions How have LEXX shares performed this year? Lexaria Bioscience's stock was trading at $2.10 at the beginning of the year. Since then, LEXX shares have decreased by 37.3% and is now trading at $1.3160. View the best growth stocks for 2025 here. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) released its quarterly earnings data on Monday, April, 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative trailing twelve-month return on equity of 88.88% and a negative net margin of 1,473.04%. Who are Lexaria Bioscience's major shareholders? Lexaria Bioscience's top institutional shareholders include Byrne Asset Management LLC (0.16%). Insiders that own company stock include Richard Christopher, Catherine C Turkel and Vanessa Carle. View institutional ownership trends. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR). Company Calendar Last Earnings4/14/2025Today4/25/2025Next Earnings (Estimated)7/11/2025Fiscal Year End8/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEXX CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+314.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net Margins-1,473.04% Pretax Margin-1,475.05% Return on Equity-88.88% Return on Assets-83.59% Debt Debt-to-Equity RatioN/A Current Ratio29.62 Quick Ratio29.62 Sales & Book Value Annual Sales$525,923.00 Price / Sales56.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.52Miscellaneous Outstanding Shares17,559,000Free Float12,919,000Market Cap$29.67 million OptionableNot Optionable Beta0.86 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:LEXX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.